Item 8.01. Other Events.

Story continues below

On May17, 2018, Tabula Rasa HealthCare,Inc. (the “Company”) was informed that Orsula V. Knowlton, President and Chief Marketing& New Business Development Officer of the Company, sold 8,000 shares of the Company’s common stock to Dr.Knowlton’s pre-arranged stock trading plan (the “Plan”) which was designed to comply with Rule10b5-1 of the Securities Exchange Act of 1934, as amended, and the Company’s insider trading policy regarding stock transactions. The Plan was previously adopted on May15, 2018, which was during the Company’s most recent open trading window period under the Company’s insider trading policy. Under the Plan, Dr.Knowlton is permitted to sell up to an aggregate of 96,000 shares of the Company’s common stock on the open market at prevailing market prices to a pre-established formula and at the times specified in her Plan. If all the shares subject to the Plan were sold, Dr.Knowlton would retain approximately 91% of her current holdings, which include vested and unvested options and shares of restricted stock.

The Plan was initiated in connection with Dr.Knowlton’s long-term strategy for asset diversification and family financial planning. Transactions under the Plan will be disclosed publicly through Form4s filed with the Securities and Exchange Commission. The Company does not undertake any obligation to report any 10b5-1 plans that may be adopted by any of the Company’s board members or executive officers in the future, or to report any modifications or terminations of any publicly announced plan, except to the extent required by law.


Tabula Rasa HealthCare, Inc. (Tabula Rasa), formerly CareKinesis, Inc., is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs. It also provides risk adjustment services, which help its clients to properly characterize a patient’s acuity, or severity of health condition, and optimize the associated payments for care. The Company serves approximately 100 healthcare organizations that focus on populations with complex healthcare needs and extensive medication requirements. Its products and services are built around the Medication Risk Mitigation Matrix, or MRM Matrix.

An ad to help with our costs